ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

PROTELOS 2 g granules for oral suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sachet contains 2 g of strontium ranelate.

Excipient: Each sachet also contains 20 mg of aspartame (E951).

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Granules for oral suspension
Yellow granules

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

PROTELOS is indicated in adults.
Treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral and hip fractures (see section 5.1).
Treatment of osteoporosis in men at increased risk of fracture (see section 5.1).

4.2 Posology and method of administration

Posology
The recommended dose is one 2 g sachet once daily by oral administration.

Due to the nature of the treated disease, strontium ranelate is intended for long-term use.

The absorption of strontium ranelate is reduced by food, milk and derivative products and therefore, PROTELOS should be administered in-between meals. Given the slow absorption, PROTELOS should be taken at bedtime, preferably at least two hours after eating (see sections 4.5 and 5.2).

Patients treated with strontium ranelate should receive vitamin D and calcium supplements if dietary intake is inadequate.

Elderly population
The efficacy and safety of strontium ranelate have been established in a broad age range (up to 100 years at inclusion) of postmenopausal women with osteoporosis. No dose adjustment is required in relation to age.

Renal impairment
Strontium ranelate is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min) (see sections 4.4 and 5.2). No dose adjustment is required in patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance) (see section 5.2).

Hepatic impairment
As strontium ranelate is not metabolised, no dose adjustment is required in patients with hepatic impairment.

**Paediatric population**
The safety and efficacy of PROTELOS in children aged below 18 years have not been established. No data are available.

**Method of administration**
For oral use.
The granules in the sachets must be taken as a suspension in a glass containing a minimum of 30 ml (approximately one third of a standard glass) of water.
Although in-use studies have demonstrated that strontium ranelate is stable in suspension for 24 hours after preparation, the suspension should be drunk immediately after being prepared.

**4.3 Contraindications**
Hypersensitivity to the active substance or to any of the excipients.
Current or previous venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism.
Temporary or permanent immobilisation due to e.g. post-surgical recovery or prolonged bed rest.

**4.4 Special warnings and precautions for use**

**Use in patients with renal impairment**
In the absence of bone safety data in patients with severe renal impairment treated with strontium ranelate, PROTELOS is not recommended in patients with a creatinine clearance below 30 ml/min (see section 5.2). In accordance with good medical practice, periodic assessment of renal function is recommended in patients with chronic renal impairment. Continuation of treatment with PROTELOS in patients developing severe renal impairment should be considered on an individual basis.

**Venous thromboembolism**
In phase III placebo-controlled studies, strontium ranelate treatment was associated with an increase in the annual incidence of venous thromboembolism (VTE), including pulmonary embolism (see section 4.8). The cause of this finding is unknown. PROTELOS is contra-indicated in patients with a past history of venous thromboembolic events (see section 4.3) and should be used with caution in patients at risk of VTE. When treating patients over 80 years at risk of VTE, the need for continued treatment with PROTELOS should be re-evaluated. PROTELOS should be discontinued as soon as possible in the event of an illness or a condition leading to immobilisation (see section 4.3) and adequate preventive measures taken. Therapy should not be restarted until the initiating condition has resolved and the patient is fully mobile. When a VTE occurs, PROTELOS should be stopped.

**Skin reactions**
Life-threatening cutaneous reactions (Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS)) have been reported with the use of PROTELOS.
Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment and usually around 3-6 weeks for DRESS
If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) or DRESS (e.g. rash, fever, eosinophilia and systemic involvement (e.g. adenopathy, hepatitis, interstitial nephropathy, interstitial lung disease) are present, PROTELOS treatment should be discontinued immediately.
The best results in managing SJS, TEN or DRESS come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis. The outcome of DRESS is favorable in most cases upon discontinuation of PROTELOS and after
initiation of corticosteroid therapy when necessary. Recovery could be slow and recurrences of the syndrome have been reported in some cases after discontinuation of corticosteroid therapy. If the patient has developed SJS, TEN or DRESS with the use of PROTELOS, PROTELOS must not be re-started in this patient at any time.

**Interaction with laboratory test**
Strontium interferes with colorimetric methods for the determination of blood and urinary calcium concentrations. Therefore, in medical practice, inductively coupled plasma atomic emission spectrometry or atomic absorption spectrometry methods should be used to ensure an accurate assessment of blood and urinary calcium concentrations.

**Excipient**
PROTELOS contains a source of phenylalanine, which may be harmful for people with phenylketonuria.

### 4.5 Interaction with other medicinal products and other forms of interaction

Food, milk and derivative products, and medicinal products containing calcium may reduce the bioavailability of strontium ranelate by approximately 60-70%. Therefore, administration of PROTELOS and such products should be separated by at least two hours (see section 5.2).

As divalent cations can form complexes with oral tetracycline and quinolone antibiotics at the gastrointestinal level and thereby reduce their absorption, simultaneous administration of strontium ranelate with these medicinal products is not recommended. As a precautionary measure, PROTELOS treatment should be suspended during treatment with oral tetracycline or quinolone antibiotics.

An *in vivo* clinical interaction study showed that the administration of aluminium and magnesium hydroxides either two hours before or together with strontium ranelate caused a slight decrease in the absorption of strontium ranelate (20-25% AUC decrease), while absorption was almost unaffected when the antacid was given two hours after strontium ranelate. It is therefore preferable to take antacids at least two hours after PROTELOS. However, when this dosing regimen is impractical due to the recommended administration of PROTELOS at bedtime, concomitant intake remains acceptable.

No interaction was observed with oral supplementation of vitamin D.

No evidence of clinical interactions or relevant increase of blood strontium levels with medicinal products expected to be commonly prescribed concomitantly with PROTELOS in the target population were found during clinical trials. These included: nonsteroidal anti-inflammatory agents (including acetylsalicylic acid), anilides (such as paracetamol), H₂ blockers and proton pump inhibitors, diuretics, digoxin and cardiac glycosides, organic nitrates and other vasodilators for cardiac diseases, calcium channel blockers, beta blockers, ACE inhibitors, angiotensin II antagonists, selective beta-2 adrenoceptor agonists, oral anticoagulants, platelet aggregation inhibitors, statins, fibrates and benzodiazepine derivatives.

### 4.6 Fertility, pregnancy and lactation

**Pregnancy**
There are no data from the use of strontium ranelate in pregnant women. At high doses, animal studies have shown reversible bone effects in the offspring of rats and rabbits treated during pregnancy (see section 5.3). If PROTELOS is used inadvertently during pregnancy, treatment must be stopped.

**Breast-feeding**
Physico-chemical data suggest excretion of Strontium ranelate in human milk. PROTELOS should not be used during breast-feeding.
Fertility
No effects were observed on males and females fertility in animal studies.

4.7 Effects on ability to drive and use machines
Strontium ranelate has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects
PROTELOS has been studied in clinical trials involving nearly 8,000 participants. Long-term safety has been evaluated in postmenopausal women with osteoporosis treated for up to 60 months with strontium ranelate 2 g/day (n=3,352) or placebo (n=3,317) in phase III studies. Mean age was 75 years at inclusion and 23% of the patients enrolled were 80 to 100 years of age.

There were no differences in the nature of adverse reactions between treatment groups regardless of whether patients were aged below or above 80 at inclusion.

Overall incidence rates for adverse reactions with strontium ranelate did not differ from placebo and adverse reactions were usually mild and transient. The most common adverse reactions consisted of nausea and diarrhoea, which were generally reported at the beginning of treatment with no noticeable difference between groups afterwards. Discontinuation of therapy was mainly due to nausea (1.3% and 2.2% in the placebo and strontium ranelate groups respectively).

In phase III studies, the annual incidence of venous thromboembolism (VTE) observed over 5 years was approximately 0.7%, with a relative risk of 1.4 (95% CI = [1.0 ; 2.0]) in strontium ranelate treated patients as compared to placebo (see section 4.4).

The following adverse reactions have been reported during clinical studies and/or post marketing use with Strontium ranelate.

Adverse reactions, defined as adverse events considered at least possibly attributable to strontium ranelate treatment in phase III studies are listed below using the following convention (frequencies versus placebo): very common (>1/10); common (>1/100, <1/10); uncommon (>1/1,000, <1/100); rare (>1/10,000, <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).

<table>
<thead>
<tr>
<th>System Organ Class (SOC)</th>
<th>Frequency category</th>
<th>Adverse Reaction</th>
<th>Percentage of Patients Experiencing the adverse reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Strontium ranelate (n=3352)</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Frequency unknown:</td>
<td>Confusional state</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Insomnia</td>
<td>-</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Common:</td>
<td>Headache</td>
<td>3.3%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disturbances in consciousness</td>
<td>2.6%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memory loss</td>
<td>2.5%</td>
</tr>
<tr>
<td></td>
<td>Uncommon:</td>
<td>Seizures</td>
<td>0.4%</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Common:</td>
<td>Venous thromboembolism (VTE)</td>
<td>2.7%</td>
</tr>
</tbody>
</table>
### Respiratory, thoracic and mediastinal disorders

*Frequency unknown:*  
Bronchial hyperreactivity

### Gastrointestinal disorders

*Common:*  
- Nausea: 7.1%  4.6%  
- Diarrhoea: 7.0%  5.0%  
- Loose stools: 1.0%  0.2%  

*Frequency unknown:*  
- Vomiting  
- Abdominal pain  
- Oral mucosal irritation (stomatitis and/or mouth ulceration)  
- Gastroesophageal reflux  
- Dyspepsia  
- Constipation  
- Flatulence

### Hepatobiliary disorders

*Frequency unknown:*  
- Serum transaminase increased (in association with hypersensitivity skin reactions)  
- Hepatitis

### Skin and subcutaneous tissue disorders

*Common:*  
- Dermatitis: 2.3%  2.0%  
- Eczema: 1.8%  1.4%

*Rare:*  
- DRESS (see section 4.4)

*Very rare:*  
- Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome and toxic epidermal necrolysis (see section 4.4)

*Frequency unknown:*  
- Hypersensitivity skin reactions (rash, pruritus, urticaria, angioedema)  
- Alopecia

### Musculoskeletal and connective tissue disorders

*Frequency unknown:*  
- Musculoskeletal pain (muscle spasm, myalgia, bone pain, arthralgia and pain in extremity)

### General disorders and administration site conditions

*Frequency unknown:*  
- Peripheral oedema  
- Pyrexia (in association with hypersensitivity skin reactions)

### Blood and Lymphatic disorders

*Frequency unknown:*  
- Bone marrow failure  
- Eosinophilia (in association with hypersensitivity skin reactions)  
- Lymphadenopathy (in association with hypersensitivity skin reactions)

### Investigations

*Common:*  
- Blood Creatine phosphokinase (CPK) increased<sup>b</sup>: 1.4%  0.6%

<sup>a</sup> Post-marketing experience  
<sup>b</sup> Musculo-skeletal fraction > 3 times the upper limit of the normal range. In most cases, these values spontaneously reverted to normal without change in treatment.
4.9 Overdose

Good tolerance was shown in a clinical study investigating the repeated administration of 4 g strontium ranelate per day over 25 days in healthy postmenopausal women. Single administration of doses up to 11 g in healthy young male volunteers did not cause any particular symptoms. Following episodes of overdoses during clinical trials (up to 4 g/day for a maximal duration of 147 days), no clinically relevant events were observed. Administration of milk or antacids may be helpful to reduce the absorption of the active substance. In the event of substantial overdose, vomiting may be considered to remove unabsorbed active substance.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for the treatment of bone diseases - Other drugs affecting bone structure and mineralisation, ATC code: M05BX03

Mechanism of action

In vitro, strontium ranelate:
- increases bone formation in bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture;
- reduces bone resorption by decreasing osteoclast differentiation and resorbing activity.

This results in a rebalance of bone turnover in favour of bone formation.

The activity of strontium ranelate was studied in various non-clinical models. In particular, in intact rats, strontium ranelate increases trabecular bone mass, trabeculae number and thickness; this results in an improvement of bone strength.

In bone tissue of treated animals and humans, strontium is mainly adsorbed onto the crystal surface and only slightly substitutes for calcium in the apatite crystal of newly formed bone. Strontium ranelate does not modify the bone crystal characteristics. In iliac crest bone biopsies obtained after up to 60 months of treatment with strontium ranelate 2 g/day in phase III trials, no deleterious effects on bone quality or mineralisation were observed.

The combined effects of strontium distribution in bone (see section 5.2) and increased X-ray absorption of strontium as compared to calcium, leads to an amplification of bone mineral density (BMD) measurement by dual-photon X-ray absorptiometry (DXA). Available data indicate that these factors account for approximately 50% of the measured change in BMD over 3 years of treatment with PROTELOS 2 g/day. This should be taken into account when interpreting BMD changes during treatment with PROTELOS. In phase III studies, which demonstrated the anti-fracture efficacy of PROTELOS treatment, measured mean BMD increased from baseline with PROTELOS by approximately 4% per year at the lumbar spine and 2% per year at the femoral neck, reaching 13% to 15% and 5% to 6% respectively after 3 years, depending on the study.

In phase III studies, as compared to placebo, biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) increased and those of bone resorption (serum C-telopeptide and urinary N-telopeptide cross links) decreased from the third month of treatment up to 3 years.

Secondary to the pharmacological effects of strontium ranelate, slight decreases in calcium and parathyroid hormone (PTH) serum concentrations, increases in blood phosphorus concentrations and in total alkaline phosphatase activity were observed, with no observed clinical consequences.
Clinical efficacy

Osteoporosis is defined as BMD of the spine or hip 2.5 SD or more below the mean value of a normal young population. A number of risk factors are associated with postmenopausal osteoporosis including low bone mass, low bone mineral density, early menopause, a history of smoking and a family history of osteoporosis. The clinical consequence of osteoporosis is fractures. The risk of fractures is increased with the number of risk factors.

Treatment of postmenopausal osteoporosis:
The anti-fracture studies program of PROTELOS was made up of two placebo-controlled phase III studies: SOTI study and TROPOS study. SOTI involved 1,649 postmenopausal women with established osteoporosis (low lumbar BMD and prevalent vertebral fracture) and a mean age of 70 years. TROPOS involved 5,091 postmenopausal women with osteoporosis (low femoral neck BMD and prevalent fracture in more than half of them) and a mean age of 77 years. Together, SOTI and TROPOS enrolled 1,556 patients over 80 years at inclusion (23.1% of the study population). In addition to their treatment (2 g/day strontium ranelate or placebo), the patients received adapted calcium and vitamin D supplements throughout both studies.

PROTELOS reduced the relative risk of new vertebral fracture by 41% over 3 years in the SOTI study (table 1). The effect was significant from the first year. Similar benefits were demonstrated in women with multiple fractures at baseline. With respect to clinical vertebral fractures (defined as fractures associated with back pain and/or a body height loss of at least 1 cm), the relative risk was reduced by 38%. PROTELOS also decreased the number of patients with a body height loss of at least 1 cm as compared to placebo. Quality of life assessment on the QUALIOST specific scale as well as the General Health perception score of the SF-36 general scale indicated benefit of PROTELOS, compared with placebo.

Efficacy of PROTELOS to reduce the risk of new vertebral fracture was confirmed in the TROPOS study, including for osteoporotic patients without fragility fracture at baseline.

Table 1: Incidence of patients with vertebral fracture and relative risk reduction

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>PROTELOS</th>
<th>Relative Risk Reduction vs. placebo (95%CI), p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SOTI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N=723</td>
<td>N=719</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New vertebral fracture over 3 years</td>
<td>32.8%</td>
<td>20.9%</td>
<td>41% (27-52), p&lt;0.001</td>
</tr>
<tr>
<td>New vertebral fracture over the 1st year</td>
<td>11.8%</td>
<td>6.1%</td>
<td>49% (26-64), p&lt;0.001</td>
</tr>
<tr>
<td>New clinical vertebral fracture over 3 years</td>
<td>17.4%</td>
<td>11.3%</td>
<td>38% (17-53), p&lt;0.001</td>
</tr>
<tr>
<td><strong>TROPOS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N=1823</td>
<td>N=1817</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New vertebral fracture over 3 years</td>
<td>20.0%</td>
<td>12.5%</td>
<td>39% (27-49), p&lt;0.001</td>
</tr>
</tbody>
</table>

In patients over 80 years of age at inclusion, a pooled analysis of SOTI and TROPOS studies showed that PROTELOS reduced the relative risk of experiencing new vertebral fractures by 32% over 3 years (incidence of 19.1% with strontium ranelate vs. 26.5% with placebo).

In an *a-posteriori* analysis of patients from the pooled SOTI and TROPOS studies with baseline lumbar spine and / or femoral neck BMD in the osteopenic range and without prevalent fracture but with at least one additional risk factor for fracture (N=176), PROTELOS reduced the risk of a first vertebral fracture by 72% over 3 years (incidence of vertebral fracture 3.6% with strontium ranelate vs. 12.0% with placebo).

An *a-posteriori* analysis was performed on a subgroup of patients from the TROPOS study of particular medical interest and at high-risk of fracture [defined by a femoral neck BMD T-score ≤ -
3 SD (manufacturer’s range corresponding to -2.4 SD using NHANES III) and an age ≥ 74 years (n=1,977, i.e. 40% of the TROPOS study population). In this group, over 3 years of treatment, PROTELOS reduced the risk of hip fracture by 36% relative to the placebo group (table 2).

<table>
<thead>
<tr>
<th>TROPOS</th>
<th>Placebo</th>
<th>PROTELOS</th>
<th>Relative Risk Reduction vs. placebo (95%CI), p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hip fracture over 3 years</td>
<td>N=995</td>
<td>N=982</td>
<td>6.4%</td>
</tr>
</tbody>
</table>

**Treatment of Osteoporosis in men:**
The efficacy of PROTELOS was demonstrated in men with osteoporosis in a 2-year, double-blind, placebo-controlled study with a main analysis after one year in 243 patients (Intention to treat population, 161 patients received strontium ranelate) at high risk of fracture (mean age 72.7 years; mean lumbar BMD T-score value of -2.6; 28% of prevalent vertebral fracture). All patients received daily supplemental calcium (1000 mg) and vitamin D (800 UI). Statistically significant increases in BMD were observed as early as 6 months following initiation of PROTELOS treatment versus placebo. Over 12 months, a statistically significant increase in mean lumbar spine BMD, main efficacy criteria (E (SE) = 5.32% (0.75); 95%CI = [3.86; 6.79]; p<0.001), similar to that observed in the pivotal anti-fracture phase III studies carried-out in postmenopausal women, was observed. Statistically significant increases in femoral neck BMD and total hip BMD (p<0.001) were observed after 12 months.

**Paediatric population**
The European Medicines Agency has waived the obligation to submit the results of studies with PROTELOS in all subsets of the paediatric population in osteoporosis (see section 4.2 for information on paediatric use).

**5.2 Pharmacokinetic properties**
Strontium ranelate is made up of 2 atoms of stable strontium and 1 molecule of ranelic acid, the organic part permitting the best compromise in terms of molecular weight, pharmacokinetics and acceptability of the medicinal product. The pharmacokinetics of strontium and ranelic acid have been assessed in healthy young men and healthy postmenopausal women, as well as during long-term exposure in men with osteoporosis and postmenopausal osteoporotic women including elderly women.

Due to its high polarity, the absorption, distribution and binding to plasma proteins of ranelic acid are low. There is no accumulation of ranelic acid and no evidence of metabolism in animals and humans. Absorbed ranelic acid is rapidly eliminated unchanged via the kidneys.

**Absorption**
The absolute bioavailability of strontium is about 25% (range 19-27%) after an oral dose of 2 g strontium ranelate. Maximum plasma concentrations are reached 3-5 hours after a single dose of 2 g. Steady state is reached after 2 weeks of treatment. Intake of strontium ranelate with calcium or food reduces the bioavailability of strontium by approximately 60-70%, compared with administration 3 hours after a meal. Due to the relatively slow absorption of strontium, food and calcium intake should be avoided both before and after administration of PROTELOS. Oral supplementation with vitamin D has no effect on strontium exposure.

**Distribution**
Strontium has a volume of distribution of about 1 l/kg. The binding of strontium to human plasma proteins is low (25%) and strontium has a high affinity for bone tissue. Measurement of strontium concentration in iliac crest bone biopsies from patients treated for up to 60 months with strontium ranelate 2 g/day indicate that bone strontium concentrations may reach a plateau after about 3 years of treatment. There are no data in patients to demonstrate elimination kinetics of strontium from bone off-therapy.

**Biotransformation**
As a divalent cation, strontium is not metabolised. Strontium ranelate does not inhibit cytochrome P450 enzymes.

**Elimination**
The elimination of strontium is time and dose independent. The effective half-life of strontium is about 60 hours. Strontium excretion occurs via the kidneys and the gastrointestinal tract. Its plasma clearance is about 12 ml/min (CV 22%) and its renal clearance about 7 ml/min (CV 28%)

**Pharmacokinetics in special clinical situations**

**Elderly**
Population pharmacokinetic data showed no relationship between age and apparent clearance of strontium in the target population.

**Patients with renal impairment**
In patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance), strontium clearance decreases as creatinine clearance decreases (approximately 30% decrease over the creatinine clearance range 30 to 70 ml/min) and thereby induces an increase in strontium plasma levels. In phase III studies, 85% of the patients had a creatinine clearance between 30 and 70 ml/min and 6% below 30 ml/min at inclusion, and the mean creatinine clearance was about 50 ml/min. No dosage adjustment is therefore required in patients with mild-to-moderate renal impairment. There is no pharmacokinetic data in patients with severe renal impairment (creatinine clearance below 30 ml/min).

**Patients with hepatic impairment**
There is no pharmacokinetic data in patients with hepatic impairment. Due to the pharmacokinetic properties of strontium, no effect is expected.

5.3 Preclinical safety data

Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.

Chronic oral administration of strontium ranelate at high doses in rodents induced bone and tooth abnormalities, mainly consisting of spontaneous fractures and delayed mineralisation. These effects were reported at bone strontium levels 2-3 times higher than long-term clinical bone strontium levels and were reversible after cessation of treatment.

Developmental toxicity studies in rats and rabbits resulted in bone and tooth abnormalities (e.g. bent long bones and wavy ribs) in the offspring. In rats, these effects were reversible 8 weeks after cessation of treatment.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Aspartame (E951)
Maltodextrin
Mannitol (E421)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

- 3 years.
- Once reconstituted in water, the suspension is stable for 24 hours. However, it is recommended to drink the suspension immediately after preparation (see section 4.2)

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Paper/polyethylene/aluminium/polyethylene sachets.

Pack sizes
Boxes containing 7, 14, 28, 56, 84 or 100 sachets.
Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

LES LABORATOIRES SERVIER
50, rue Carnot
92284 Suresnes cedex
France

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/288/001
EU/1/04/288/002
EU/1/04/288/003
EU/1/04/288/004
EU/1/04/288/005
EU/1/04/288/006

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21/09/2004
Date of renewal: 21/09/2009

10. DATE OF REVISION OF THE TEXT
Detailed information on this medicinal product is available on the website of the European Medicines Agency  http://www.ema.europa.eu
ANNEX II

A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OF THE MARKETING AUTHORITY
A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Les Laboratoires Servier Industrie
905, route de Saran
45520 Gidy
France

B. CONDITIONS OF THE MARKETING AUTHORISATION

- CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER

Medicinal product subject to medical prescription

- CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Not applicable

- OTHER CONDITIONS

Pharmacovigilance system:
The MAH must ensure that the system of Pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before and whilst the medicinal product is on the market.

Risk Management Plan (RMP)
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, in the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP.

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the following Periodic Safety Update Report (PSUR).
In addition, an updated RMP should be submitted:
- When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities,
- Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached,
- At the request of the European Medicines Agency.

PSURs
The MAH will continue to submit 6 monthly PSURs, unless otherwise specified by the Committee for Medicinal Products for Human Use (CHMP).
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

PROTELOS 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
7 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use

![Image of method and route of administration]

<table>
<thead>
<tr>
<th>Week</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td></td>
</tr>
<tr>
<td>Tuesday</td>
<td></td>
</tr>
<tr>
<td>Wednesday</td>
<td></td>
</tr>
<tr>
<td>Thursday</td>
<td></td>
</tr>
<tr>
<td>Friday</td>
<td></td>
</tr>
<tr>
<td>Saturday</td>
<td></td>
</tr>
<tr>
<td>Sunday</td>
<td></td>
</tr>
</tbody>
</table>
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/04/288/001

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

PROTELOS 2 g
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

PROTELOS 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
14 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use

![Image of instructions]

<table>
<thead>
<tr>
<th>Week</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
<th>Sunday</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19
6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/04/288/002

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

PROTELOS 2 g
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Outer carton

1. NAME OF THE MEDICINAL PRODUCT

PROTELOS 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
28 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use

<table>
<thead>
<tr>
<th>Week</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
<th>Sunday</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Les Laboratoires Servier  
50, rue Carnot  
92284 Suresnes cedex  
France

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/04/288/003

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

PROTELOS 2 g
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

PROTELOS 2 g granules for oral suspension
Strontium ranelate

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each sachet contains 2 g strontium ranelate.

3. LIST OF EXCIPIENTS

Also contains aspartame (E 951).

4. PHARMACEUTICAL FORM AND CONTENTS

Granules for oral suspension.
56 sachets
84 sachets
100 sachets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral use
Read the package leaflet before use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/288/004 56 sachets
EU/1/04/288/005 84 sachets
EU/1/04/288/006 100 sachets

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

PROTELOS 2 g
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Sachet

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

PROTELOS 2 g granules for oral suspension.
Strontium ranelate.
For oral use.

2. METHOD OF ADMINISTRATION

Read the package leaflet before use

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Batch

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

2 g

6. OTHER
B. PACKAGE LEAFLET
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or your pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or your pharmacist.

In this leaflet:
1. What PROTELOS is and what it is used for
2. Before you take PROTELOS
3. How to take PROTELOS
4. Possible side effects
5. How to store PROTELOS
6. Further information

1. WHAT PROTELOS IS AND WHAT IT IS USED FOR

PROTELOS is a non-hormonal medicine used to treat osteoporosis:
- in postmenopausal women to reduce the risk of fracture at the spine and at the hip;
- in men at increased risk of fracture.

About osteoporosis
Your body is constantly breaking down old bone and making new bone tissue. If you have osteoporosis, your body breaks down more bone than it forms so that gradually bone loss occurs and your bones become thinner and fragile. This is especially common in women after the menopause. Many people with osteoporosis have no symptoms and you may not even know that you have it. However, osteoporosis makes you more likely to have fractures (break bones), especially in your spine, hips and wrists.

How PROTELOS works
PROTELOS, which contains the substance strontium ranelate, belongs to a group of medicines used to treat bone diseases. PROTELOS works by reducing bone breakdown and stimulating rebuilding of bone and therefore reduces the risk of fracture. The newly formed bone is of normal quality.

2. BEFORE YOU TAKE PROTELOS

Do not take PROTELOS:
- if you are allergic (hypersensitive) to strontium ranelate or any of the other ingredients of PROTELOS.
- if you have or have had a blood clot (for example, in the blood vessels in your legs or lungs).
- if you are immobilised permanently or for some time such as being wheel-chair bound, or confined to bed or if you are to undergo an operation or recovering from an operation. The risk of vein thrombosis (blood clots in the leg or lungs) may be increased in the event of lengthy immobilisation.
**Take special care with PROTELOS:**
Before taking PROTELOS talk to your doctor:
- if you have severe kidney disease.

During treatment, if you experience an allergic reaction (such as swelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), you must immediately stop taking PROTELOS and seek medical advice.

Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis and severe hypersensitivity reactions (DRESS)) have been reported with the use of PROTELOS. Stevens-Johnson syndrome and toxic epidermal necrolysis appear initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin.

DRESS appears initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.

The highest risk of occurrence of serious skin reactions is within the first weeks of treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis and usually around 3-6 weeks for DRESS. If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis or DRESS with the use of PROTELOS, you must not be re-started on PROTELOS at any time.

If you develop a rash or these skin symptoms, stop taking PROTELOS, seek urgent advice from a doctor and tell him that you are taking this medicine.

**Use in children**
PROTELOS is not intended for use in children and adolescents (below the age of 18).

**Taking other medicines:**
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

- You should stop taking PROTELOS if you have to take oral tetracyclines or quinolones (two types of antibiotics). You can take PROTELOS again when you have finished taking these antibiotics. If you are unsure about this ask your doctor or pharmacist.

- If you are taking medicines containing calcium, you should leave at least 2 hours before you take PROTELOS.

- If you take antacids (medicines to relieve heartburn) you should take them at least 2 hours after PROTELOS. If this is not possible, it is acceptable to take the two medicines at the same time.

**Taking PROTELOS with food and drink:**
Food, milk and milk products reduce the absorption of strontium ranelate. It is recommended that you take PROTELOS in-between meals, preferably at bedtime at least two hours after food, milk or milk products or calcium supplements.

**Pregnancy and breast-feeding:**
Do not take PROTELOS during pregnancy or when you are breastfeeding. If you take it by accident during pregnancy or breastfeeding, stop taking it straight away and talk to your doctor.

**Driving and using machines:**
Protelos is unlikely to affect your ability to drive or use machines.

**Important information about some of the ingredients of PROTELOS:**
PROTELOS contains aspartame. If you suffer from phenylketonuria (a rare, hereditary disorder of the metabolism) talk to your doctor before you start to take this medicine.
3. **HOW TO TAKE PROTELOS**

Always take PROTELOS exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

PROTELOS is for oral use.

The recommended dose is one 2g sachet a day.

It is recommended that you take PROTELOS at bedtime, preferably at least 2 hours after dinner. You may lie down immediately after taking PROTELOS if you wish.

Take the granules contained in the sachets as a suspension in a glass of water (see instructions below). PROTELOS can interact with milk and milk products, so it is important that you mix PROTELOS only with water to be sure it works properly.

1. Empty the granules from the sachet into a glass;

2. Add water;

3. Stir until the granules are evenly dispersed in the water.

Drink straight away. You should not leave it more than 24 hours before you drink it. If for some reason you cannot drink the medicine straight away, make sure you stir it again before drinking.

Your doctor may advise you to take calcium and vitamin D supplements in addition to PROTELOS. Do not take calcium supplements at bedtime, at the same time as PROTELOS.

Your doctor will tell you how long you should continue to take PROTELOS. Osteoporosis-therapy is usually required for a long period. It is important that you continue taking PROTELOS for as long as your doctor prescribes the medicine.

**If you take more PROTELOS than you should:**

If you take too many sachets of PROTELOS, tell your doctor or pharmacist. They may advise you to drink milk or take antacids to reduce the absorption of the active ingredient.

**If you forget to take PROTELOS:**

Do not take a double dose to make up for forgotten individual doses. Just carry on with the next dose at the normal time.

4. **POSSIBLE SIDE EFFECTS**

Like all medicines, PROTELOS can cause side effects, although not everybody gets them.

The frequency of possible side effects listed below is defined using the following convention:

- very common (affects more than 1 user in 10)
- common (affects 1 to 10 users in 100)
uncommon (affects 1 to 10 users in 1,000)
rare (affects 1 to 10 users in 10,000)
very rare (affects less than 1 user in 10,000)
not known (frequency cannot be estimated from the available data)

**Common:**
Blood clots. Signs of a blood clot include painful swelling in your leg, sudden chest pain or difficulty breathing. See a doctor straight away if you experience any of these symptoms.
Nausea, diarrhoea, headache, skin irritation, memory troubles, fainting fit.
However, these effects were mild and short-lived and usually did not cause the patients to stop taking their treatment. Talk to your doctor if any effects become troublesome or persist.

**Uncommon:**
Seizures.

**Rare:**
Severe hypersensitivity reactions (DRESS: see section 2)

**Very rare:**
Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (see section 2).

**Not known:**
Vomiting, abdominal pain, reflux, indigestion, constipation, flatulence, difficulty in sleeping, inflammation of the liver (hepatitis), oral irritation (such as mouth ulcers and gum inflammation), bone, muscle and/or joint pain, muscle cramps, hair loss, reduction in production of blood cells in the bone marrow, itching, hives, blistering, angioedema (such as swollen face, tongue or throat, difficulty in breathing or swallowing), swelling in limbs, feeling confused, bronchial hyperreactivity (symptoms include wheezing and shortness of breath).

If you have stopped treatment due to hypersensitivity reactions, do not take PROTELOS again

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. **HOW TO STORE PROTELOS**

Keep out of the reach and sight of children.

This medicinal product does not require any special storage conditions.

Do not use after the expiry date which is stated on the box and the sachet after EXP.
Once reconstituted in water, the suspension is stable for 24 hours. However, it is recommended to drink the suspension immediately after preparation (see section 3)

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. **FURTHER INFORMATION**

**What PROTELOS contains**
- The active substance is strontium ranelate. Each sachet contains 2 g of strontium ranelate.
- The other ingredients are aspartame (E 951), maltodextrin, mannitol (E 421).

**What PROTELOS looks like and contents of the pack**

PROTELOS is available in sachets containing yellow granules for oral suspension. PROTELOS is supplied in boxes of 7, 14, 28, 56, 84 or 100 sachets.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

**Marketing Authorisation Holder**
Les Laboratoires Servier  
50, rue Carnot  
92284 Suresnes cedex  
France

**Manufacturer**
Les Laboratoires Servier Industrie  
905, route de Saran  
45520 Gidy  
France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

**België/Belgique/Belgien**  
S.A. Servier Benelux N.V.  
Tel: +32 (0)2 529 43 11

**Luxembourg/Luxemburg**  
S.A. Servier Benelux N.V.  
Tel: +32 (0)2 529 43 11

**България**  
Сервие Медикал ЕООД  
Тел.: +359 2 921 57 00

**Magyarország**  
Servier Hungaria Kft.  
Tel: +36 1 238 7799

**Česká republika**  
Servier s.r.o.  
Tel: +420 222 118 111

**Malta**  
Galepharma Ltd  
Tel: +(356) 21 247 082

**Danmark**  
Servier Danmark A/S  
Tlf: +45 36 44 22 60

**Nederland**  
Servier Nederland Farma B.V.  
Tel: +31 (0)71 5246700

**Deutschland**  
Servier Deutschland GmbH  
Tel: +49 (0)89 57095 01

**Norge**  
Servier Danmark A/S  
Tlf: +45 36 44 22 60

**Österreich**  
Servier Austria GmbH  
Tel: +43 (1) 524 39 99

**Ελλάδα**  
ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΠΕ  
Τηλ: +30 210 939 1000

**Polska**  
Servier Polska Sp. z o.o.  
Tel: +48 (0) 22 594 90 00

**España**  
Laboratorios Servier S.L.  
Tel: +34 91 748 96 30

**Portugal**  
Servier Portugal, Lda  
Tel.: +351 21 312 20 00
France
Les Laboratoires Servier
Tel: +33 (0)1 55 72 60 00

România
Servier Pharma SRL
Tel: +40 21 528 52 80

Ireland
Servier Laboratories (Ireland) Ltd.
Tel: +353 (0)1 6638110

Slovenija
Servier Pharma d.o.o.
Tel.: +386 (0)1 563 48 11

Ísland
Servier Laboratories
c/o Icepharma hf
Simi: +354 540 8000

Slovenská republika
Servier Slovensko spol. s r.o.
Tel.:+421 (0)2 5920 41 11

Italia
Servier Italia S.p.A.
Tel: +39 (06) 669081

Suomi/Finland
Servier Finland Oy
Puh/Tel: +358 (0)9 279 80 80

Κύπρος
Χ.Α.Παπαέλληνας & Σία Λτδ
Τηλ: +357 22741741

Sverige
Servier Sverige AB
Tel: +46 (8) 52 25 08 00

Latvija
SIA Servier Latvia
Tel. +371 67502039

United Kingdom
Servier Laboratories Ltd
Tel: +44 (0)1753 666409

Lietuva
UAB “SERVIER PHARMA”
Tel: +370 (5) 2 63 86 28

This leaflet was last approved in[date]

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu